Your browser doesn't support javascript.
loading
Repurposing chemotherapy-induced peripheral neuropathy grading.
Velasco, Roser; Argyriou, Andreas A; Cornblath, David R; Bruna, Pere; Alberti, Paola; Rossi, Emanuela; Merkies, Ingemar S J; Psimaras, Dimitri; Briani, Chiara; Lalisang, Roy I; Schenone, Angelo; Cavaletti, Guido; Bruna, Jordi.
Afiliación
  • Velasco R; Unit of Neuro-Oncology, Hospital Universitari de Bellvitge-Institut Català Oncologia, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Argyriou AA; Neurological Department, Agios Andreas General Hospital of Patras, Patras, Greece.
  • Cornblath DR; Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
  • Bruna P; Department of Physics, Barcelona Research Center in Multiscale Science and Engineering, Universitat Politècnica de Catalunya (UPC), BarcelonaTech, Institut de Tècniques Energètiques, Barcelona, Spain.
  • Alberti P; Department of Neuroscience and Biomedical Technologies, University of Milano-Bicocca, Monza, Italy.
  • Rossi E; Center of Biostatistics for Clinical Epidemiology, Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy.
  • Merkies ISJ; Department of Neurology, Maastricht University Medical Center+, Maastricht, Limburg, the Netherlands.
  • Psimaras D; Institute of Neurology, Unité INSERM U1127, CNRS UMR 7225 (Institut du Cerveau et de la Moelle épinière) and OncoNeuroTox Group, Center for Patients With Neurological Complications of Oncologic Treatments, Hôpitaux Universitaires la Pitié Salpêtrière, Paris, France.
  • Briani C; Department of Neurosciences, University of Padua, Padua, Italy.
  • Lalisang RI; Division of Medical Oncology, Department of Internal Medicine, GROW-School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Schenone A; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal and Infantile Sciences, University of Genoa and IRCCS San Martino Hospital, Genoa, Italy.
  • Cavaletti G; Department of Neuroscience and Biomedical Technologies, University of Milano-Bicocca, Monza, Italy.
  • Bruna J; Unit of Neuro-Oncology, Hospital Universitari de Bellvitge-Institut Català Oncologia, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Barcelona, Spain.
Eur J Neurol ; : e16457, 2024 Sep 16.
Article en En | MEDLINE | ID: mdl-39282967
ABSTRACT
BACKGROUND AND

PURPOSE:

Chemotherapy-induced peripheral neuropathy (CIPN) is perceived differently by patients and physicians, complicating its assessment. Current recommendations advocate combining clinical and patient-reported outcomes measures, but this approach can be challenging in patient care. This multicenter European study aims to bridge the gap between patients' perceptions and neurological impairments by aligning both perspectives to improve treatment decision-making.

METHODS:

Data were pooled from two prospective studies of subjects (n = 372) with established CIPN. Patient and physician views regarding CIPN were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Total Neuropathy Scale-clinical version (TNSc) items, and the disease-specific quality of life - Chemotherapy-Induced Peripheral Neuropathy questionnaire (QLQ-CIPN20) from the European Organization for Research and Treatment of Cancer (EORTC). To identify inherent neurotoxic severity patterns, we employed hierarchical cluster analysis optimized with k-means clustering and internally validated by discriminant functional analysis.

RESULTS:

Both NCI-CTCAE and TNSc demonstrated a significant difference in the distribution of severity grades in relation to QLQ-CIPN20 scores. However, a proportion of subjects with different neurotoxic severity grades exhibited overlapping QLQ-CIPN20 scores. We identified three distinct clusters classifying subjects as having severely impaired, intermediately impaired, and mildly impaired CIPN based on TNSc and QLQ-CIPN20 scores. No differences in demographics, cancer type distribution, or class of drug received were observed.

CONCLUSIONS:

Our results confirm the heterogeneity in CIPN perception between patients and physicians and identify three well-differentiated subgroups of patients delineated by degree of CIPN impairment based on scores derived from TNSc and QLQ-CIPN20. A more refined assessment of CIPN could potentially be achieved using the calculator tool derived from the cluster equations in this study. This tool, which facilitates individual patient classification, requires prospective validation.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur J Neurol Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur J Neurol Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido